摘要
目的:探讨无乳糖奶粉佐治轮状病毒(rotavirus,RV)性肠炎合并乳糖不耐受(lactose intolerance,LI)的临床疗效.方法:选取2010-10/2012-12门诊病例90例RV性肠炎合并LI患者作为研究对象,按照随机数字表法将患儿分为葡萄糖酸锌组、无乳糖奶粉组及联合组,每组各30例.3组患儿均进行常规口服补液,口服乳糖酶、双歧三联活菌等.在此基础上,葡萄糖酸锌组患儿给予葡萄糖酸锌口服液治疗,无乳糖奶粉组患儿给予无乳糖奶粉治疗,联合组患儿给予葡萄糖酸锌口服液联合无乳糖奶粉治疗.比较3组患儿临床疗效、总病程、临床症状缓解时间以及治疗前后心肌酶谱[天门冬氨酸氨基转移酶(aspartate aminotransferase,AST)、乳酸脱氢酶(lactic dehydrogenase,LDH)、肌酸激酶(creatine kinase,CK)及同工酶(creatine kinase-MB,CK-MB)]变化情况.结果:葡萄糖酸锌组和无乳糖奶粉组患儿总有效率均显著低于联合组,(83.33%vs96.67%),(80.00%vs 96.67%),差异具有统计学意义(P<0.05);葡萄糖酸锌组和无乳糖奶粉组患儿总病程和临床症状缓解时间均显著长于联合组,(7.32 d±2.14 d)vs(5.52 d±1.81 d)、(5.15 d±0.46 d)vs(3.18 d±0.77d),(7.41 d±2.03 d)vs(5.52 d±1.81 d)、(5.23 d±0.44 d)vs(3.18 d±0.77 d)(P<0.05),差异具有统计学意义(P<0.05);3组患儿治疗后AST、LDH、CK及CK-MB水平均显著下降,与治疗前比较,(39.66 U/L±3.28 U/L)vs(64.02 U/L±5.75 U/L)、(108.25 U/L±10.18U/L)vs(161.08 U/L±12.17 U/L)、(117.27U/L±9.86 U/L)vs(153.59 U/L±12.85 U/L)、(32.55 U/L±3.50 U/L)vs(57.45 U/L±6.77 U/L),(40.17 U/L±3.31 U/L)vs(63.89U/L±5.63 U/L)、(112.27 U/L±11.08 U/L)vs(160.12 U/L±12.49 U/L)、(120.07 U/L±9.92 U/L)vs(153.62 U/L±12.80 U/L)、(33.06 U/L±3.52 U/L)vs(57.68 U/L±6.73U/L),(26.75 U/L±2.68 U/L)vs(64.11 U/L±5.88 U/L)、(86.88 U/L±6.30 U/L)vs(159.62U/L±12.30 U/L)、(87.20 U/L±6.34 U/L)vs(154.10 U/L±12.97 U/L)、(24.11 U/L±2.62U/L)vs(57.56 U/L±6.39 U/L),差异具有统计学意义(P<0.05);葡萄糖酸锌组和无乳糖奶粉组患儿治疗后AST、LDH、CK及CKM B水平均显著高于联合组,(39.66 U/L±3.28 U/L)vs(26.75 U/L±2.68 U/L)、(108.25U/L±10.18 U/L)vs(86.88 U/L±6.30 U/L)、(117.27 U/L±9.86 U/L)vs(87.20 U/L±6.34U/L)、(32.55 U/L±3.50 U/L)vs(24.11 U/L±2.62 U/L),(40.17 U/L±3.31 U/L)vs(26.75U/L±2.68 U/L)、(112.27 U/L±11.08 U/L)vs(86.88 U/L±6.30 U/L)、(120.07 U/L±9.92 U/L)vs(87.20 U/L±6.34 U/L)、(33.06U/L±3.52 U/L)vs(24.11 U/L±2.62 U/L),差异具有统计学意义(P<0.05).结论:无乳糖奶粉佐治RV性肠炎合并乳糖不耐受,临床疗效显著,可有效缩短患儿总病程,快速缓解临床症状并改善患儿心肌酶谱,值得临床推广.
AIM： To explore the effects of lactose-free milk in adjunctive treatment of infants with rotavirus enteritis and lactose intolerance（RV-SLI）.METHODS： Ninety patients with RV-SLI were randomly divided into three groups： a zinc gluconate group（n = 30）, a lactose-free milk group（n = 30） and a combination group（n = 30）. All the patients were treated with conventional oral rehydration solution, oral lactase, and bifid triple viable. On the basis of this treatment, the zinc gluconate group was treated with zinc gluconate, the lactose-free milk group was treated with lactose-free milk powder, and the combination group was treated with zinc gluconate and lactose-free milk powder. The clinical effects, total course, time to relief of clinical symptoms, and myocardial enzyme spectrum [aspartate aminotransferase（AST）, lactic dehydrogenase（LDH）, creatine kinase（CK）, creatine kinase-MB（CK-MB）] were compared before and after treatment for the two groups.RESULTS： The effective rates rate for the two monotherapy groups were significantly lower than that for the combination group（83.33%, 80.00% vs 96.67%, P 0.05）. The total course and time to relief of clinical symptoms were significantly longer in the two monotherapy groups than in the combination group（7.32 d ± 2.14 d, 7.41 d ± 2.03 d vs 5.52 d ± 1.81 d; 5.15 d ± 0.46 d, 5.23 d ± 0.44 d vs 3.18 d ± 0.77 d; P 0.05）. AST, LDH, CK and CK-MB levels were significantly lower after treatment than prior treatment in all the three groups（39.66 U/L ± 3.28 U/L vs 64.02 U/L ± 5.75 U/L, 108.25 U/L ± 10.18 U/L vs 161.08 U/L ± 12.17 U/L, 117.27 U/L ± 9.86 U/L vs 153.59 U/L ± 12.85 U/L, 32.55 U/L ± 3.50 U/L vs 57.45 U/L ± 6.77 U/L, 40.17 U/L ± 3.31 U/L vs 63.89 U/L ± 5.63 U/L, 112.27 U/L ± 11.08 U/L vs 160.12 U/L ± 12.49 U/L, 120.07 U/L ± 9.92 U/L vs 153.62 U/L ± 12.80 U/L, 33.06 U/L ± 3.52 U/L vs 57.68 U/L ± 6.73 U/L, 26.75 U/L ± 2.68 U/L vs 64.11 U/L ± 5.88 U/L, 86.88 U/L ± 6.30 U/L vs 159.62 U/L ± 12.30 U/L, 87.20 U/L ± 6.34 U/L vs 154.10 U/L ± 12.97 U/L, 24.11 U/L ± 2.62 U/L vs 57.56 U/L ± 6.39 U/L; P 0.05）. AST, LDH, CK and CK-MB after treatment were significantly higher in the two monotherapy groups than in the combination group（39.66 U/L ± 3.28 U/L, 40.17 U/L ± 3.31 U/L vs 26.75 U/L ± 2.68 U/L; 108.25 U/L ± 10.18 U/L, 112.27 U/L ± 11.08 U/L vs 86.88 U/L ± 6.30 U/L; 117.27 U/L ± 9.86 U/L, 120.07 U/L ± 9.92 U/L vs 87.20 U/L ± 6.34 U/L; 32.55 U/L ± 3.50 U/L, 33.06 U/L ± 3.52 U/L vs 24.11 U/L ± 2.62 U/L; P 0.05）.CONCLUSION： Lactose-free mild has good effects in adjunctive treatment of infants with rotavirus enteritis and lactose intolerance, and it can shorten the total course and improve clinical symptoms and myocardial enzyme spectrum.
出处
《世界华人消化杂志》
CAS
北大核心
2014年第31期4853-4857,共5页
World Chinese Journal of Digestology
关键词
无乳糖奶粉
轮状病毒性肠炎
乳糖不耐受
临床疗效
Lactose-free milk powder
Rotavirus enteritis
Lactose intolerance
Clinical effect
